McKesson Announces New President of U.S. Pharmaceutical Business
Mark Walchirk to Lead McKesson's Largest Operating Unit
SAN FRANCISCO--(BUSINESS WIRE)-- McKesson Corporation (NYS: MCK) today announced that Mark Walchirk has been named president, McKesson U.S. Pharmaceutical, effective immediately. Walchirk, who was most recently chief operating officer of McKesson Specialty Health, has held numerous leadership roles at McKesson for the last 11 years, including chief operating officer of McKesson U.S. Pharmaceutical. Walchirk succeeds Brian Tyler, who was recently appointed executive vice president of corporate strategy and business development, McKesson Corporation.
Walchirk will report to Paul Julian, executive vice president and group president, McKesson Corporation. He will oversee McKesson's largest business, which supplies branded, generic and over-the-counter pharmaceuticals and value-added business, clinical and connectivity solutions to more than 40,000 customers, including retail chains, independent retail pharmacies, hospitals, health systems, integrated delivery networks and long-term care providers.
"With past roles as chief operating officer of McKesson U.S. Pharmaceutical and McKesson Specialty Health, Mark Walchirk has deep leadership experience in our pharmaceutical distribution business and a proven track record of delivering results for our customers," said Paul Julian, executive vice president and group president, McKesson Corporation. "Mark's significant experience coupled with his commitment to operational excellence and our customers' success make him the ideal choice to lead McKesson U.S. Pharmaceutical."
Walchirk joined McKesson in 2001 and spent more than eight years in progressive leadership roles within McKesson's U.S. Pharmaceutical business before being appointed president of McKesson Specialty Care Solutions in 2009. He led McKesson's integration of US Oncology and assumed the role of chief operating officer for the newly combined organization, McKesson Specialty Health. In this role, he helped lead the business to record growth and introduce new solutions that empower the community patient care delivery system.
As senior vice president and chief operating officer of McKesson U.S. Pharmaceutical, Walchirk led the integration of regional distributors D&K Healthcare and McQueary Bros., contributed to the dramatic growth of McKesson's Health Mart franchise, led the expansion of McKesson's pharmaceutical distribution business in the institutional market, and guided McKesson to industry-leading levels of accuracy and efficiency across the company's nationwide distribution network.
Before joining McKesson, Walchirk spent 13 years in medical-surgical distribution and manufacturing with Baxter Healthcare, Allegiance Healthcare and Encompass Group, holding various leadership positions in sales, marketing, operations and business development.
Walchirk earned his BS in business administration from the University of Illinois in 1988 and currently serves on the board of the Center for Healthcare Supply Chain Research and GS1 Healthcare US.
McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit http://www.mckesson.com.
KEYWORDS: United States North America California
The article McKesson Announces New President of U.S. Pharmaceutical Business originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.